0 items in cart
HUTCHMED (China) Limited Sponsored ADR [HCM]
Reports for Purchase
Showing records 1 - 20 ( 96 total )
Company: HUTCHMED (China) Limited Sponsored ADR
Continued H124 execution; well on-track to meet targets
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 10.00
Company: HUTCHMED (China) Limited Sponsored ADR
RD day highlights prospects for key late-stage products
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 10.00
Company: HUTCHMED (China) Limited Sponsored ADR
Data at EHA 2024 heighten focus on sovleplenib
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 50.00
Company: HUTCHMED (China) Limited Sponsored ADR
Strong US Fruzaqla Q1; EU approval could come soon
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 10.00
Company: HUTCHMED (China) Limited Sponsored ADR
Executing consistently on the road to breakeven
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 50.00
Company: HUTCHMED (China) Limited Sponsored ADR
FY23 results point to strong financials and fundamentals
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 10.00
Company: HUTCHMED (China) Limited Sponsored ADR
Fruquintinib clinical and commercial updates
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 10.00
Company: HUTCHMED (China) Limited Sponsored ADR
Optimized Entry and Exit Levels for HCM 112123
Provider: Stock Traders Daily
Analyst: Research Department
Price: 12.50
Company: HUTCHMED (China) Limited Sponsored ADR
Landmark FDA approval for fruquintinib
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: HUTCHMED (China) Limited Sponsored ADR
Surfing the ?waves? towards profitability
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: HUTCHMED (China) Limited Sponsored ADR
Delivering on sharpened goals and priorities
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: HUTCHMED (China) Limited Sponsored ADR
2023: a growing body of evidence for fruquintinib
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 12.50
Company: HUTCHMED (China) Limited Sponsored ADR
Significant 2022 achievements catalyse a promising 2023
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 12.50
Company: HUTCHMED (China) Limited Sponsored ADR
Delivering commercially and strategically during FY22
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: HUTCHMED (China) Limited Sponsored ADR
Takeda licenses fruquintinib in $1.13bn ex-China deal
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: HUTCHMED (China) Limited Sponsored ADR
First steps towards fruquintinib availability in the US
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: HUTCHMED (China) Limited Sponsored ADR
First steps towards fruquintinib availability in the US
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: HUTCHMED (China) Limited Sponsored ADR
A sharper focus on the path to profitability
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: HUTCHMED (China) Limited Sponsored ADR
Fruquintinib should continue to bear fruit
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: HUTCHMED (China) Limited Sponsored ADR
FRESCO-2 data support broad uptake in later-line mCRC
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 12.50